More Market Access Articles

Market Access

Face Value

Danielle Barron, (Feb 21, 2017)

With oncology drug prices under intense and growing scrutiny, how are companies proving the value of their medicines?
Market Access

Strength in Numbers

Danielle Barron, (Feb 20, 2017)

R&D innovation is being accelerated through the nurturing of a ground breaking public-private relationship
Market Access

Access All Areas

Deirdre Coleman, (Feb 15, 2017)

Numerous barriers impede the full realization of benefit from Real World Evidence
Market Access

The Price of Everything and the Value of Nothing

Hugh Gosling, (Feb 9, 2017)

What is value and how do we prove it? Economist Dr Jason Shafrin talks prices, politics and the problem of monopolies.
Market Access

Real-World Revolution Part 2

Deirdre Coleman, (Jan 23, 2017)

Changing mindsets in clinical research
Market Access

Real-World Revolution

Deirdre Coleman, (Jan 19, 2017)

Part 1 of a 2 part series: Unlock valuable insights throughout the lifecycle
Market Access

Singing in Harmony

Adam Hill, (Jan 5, 2017)

Will EUnetHTA succeed in harmonizing the value assessment of medicines across the European Union?
Market Access

Adapt or Die: Real-World Evidence Across the Lifecycle

Deirdre Coleman, (Dec 20, 2016)

The regulator’s view of real-world evidence
Market Access

Mind the Gap

Adam Hill, (Dec 13, 2016)

The importance of real-world evidence in market access is growing, but what rules can pharma follow to close the evidence gaps?